Search clinical trials for: Non-Small Cell Lung Carcinoma (NSCLC)

Total 115939 results

Amgen
Parexel

Withdrawn

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
Kura Oncology, Inc.

Withdrawn

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NSCLC

United States
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
BeiGene

Recruiting

A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China, Korea, Republic of
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)

Non Small Cell Lung Cancer Metastatic | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

France
Qian Chu

Completed

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NSCLC

China
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Frontier Science Foundation, Hellas

Completed

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

Non-small Cell Lung Cancer Stage III

Switzerland, Netherlands, Spain, Belgium, Germany
Beta Pharma Shanghai

Completed

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

NSCLC

China
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States
University of Michigan Rogel Cancer Center

Terminated

Phase I/II Calcitriol in Lung Cancer

Non Small Cell Lung Cancer

United States
University of Cologne

Completed

Molecular Imaging With Erlotinib and Bevacizumab (MIMEB)

Non-Small-Cell Lung Carcinoma

Germany
National Taiwan University Hospital

Unknown

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Taiwan
Alliance Foundation Trials, LLC.
AstraZeneca

Active, not recruiting

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer

United States
University of Milano Bicocca

Recruiting

Prospective Evaluation of Single Cell Mutations in a Panel of Known Oncogenes in NSCLC Surgical Specimens (TAP-NSCLC)

NSCLC

Italy
yu gengsheng

Recruiting

Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Stage IV | Thoracic Radiotherapy

China
Geneplus-Beijing Co. Ltd.
Shanghai Chest Hospital

Completed

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Lung Neoplasms | Adenocarcinoma of Lung | Lung Cancer, Nonsmall Cell | Squamous Cell Lung Cancer

China
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Sanofi

Terminated

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Non-small Cell Lung Cancer (NSCLC)

Netherlands
Spectrum Pharmaceuticals, Inc

Withdrawn

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States, Russian Federation
University Hospital, Geneva

Unknown

Lung Cancer Rehabilitation Study (LCRS)

Non Small Cell Lung Cancer

Switzerland
NovaRx Corporation

No longer available

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

Non-small Cell Lung Cancer

United States
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
National Cancer Institute (NCI)

Terminated

Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States
University of Athens

Completed

Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC

Non-small Cell Lung Cancer | Unresectable Malignant Neoplasm

Greece
Regeneron Pharmaceuticals
Sanofi

Terminated

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, Italy, Lithuania
Zhejiang Cancer Hospital

Not yet recruiting

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung
Alexander Chi

Not yet recruiting

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage II

China
LianBio LLC

Recruiting

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Advanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung Cancer

China
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO)

Non Small Cell Lung Cancer

Italy
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ALK-positive NSCLC

Belgium, Spain, Italy, Australia, United States, Hong Kong, Canada, Singapore
Biocad

Completed

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Ukraine, Belarus, India, Russian Federation
Gruppo Oncologico Italiano di Ricerca Clinica
Bioikos Ambiente Srl; Istituto Toscano Tumori; Temas srl; Mipharm S.p.A.; Bristol...

Active, not recruiting

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) (EDEN)

Squamous Non-small Cell Lung Cancer

Italy
Betta Pharmaceuticals Co., Ltd.

Unknown

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Non-Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (EFLRWR)

NSCLC Stage IV | NSCLC Stage IIIB | ALK Positive

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2)

Non Small Cell Lung Cancer

Italy
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
HUYABIO International, LLC.

Active, not recruiting

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer (HBI-8000)

Non Small Cell Lung Cancer

United States
Jianguo Sun

Completed

Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.

Stage III Non-small-cell Lung Cancer
RTOG Foundation, Inc.
Bristol-Myers Squibb

Terminated

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

Non-Small Cell Lung Cancer

United States
Mirati Therapeutics Inc.

Completed

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Hungary, United Kingdom, Italy, Australia, Taiwan, Poland, Canada
National Taiwan University Hospital

Completed

Selumetinib in Combination With Gefitinib in NSCLC Patients

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Genentech, Inc.

Completed

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Non-Small Cell Lung Cancer
HiberCell, Inc.

Completed

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NSCLC

United States, Germany
Hellenic Oncology Research Group

Completed

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Non-small-cell Lung Cancer

Greece
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Unknown

Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection (ZTOG-1202)

Non-small Cell Lung Cancer Stage IIIA

China
Achieve Life Sciences

Completed

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada
Royal Marsden NHS Foundation Trust
Bristol-Myers Squibb

Active, not recruiting

SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United Kingdom

Search clinical trials for: Non-Small Cell Lung Carcinoma (NSCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations